DOI:
10.1055/s-00000011
DMW - Deutsche Medizinische Wochenschrift
LinksClose Window
References
Stintzing S, Modest DP, Rossius L. et al.
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3).
Lancet Oncol 2016;
17: 1426-1434
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.